Picture of AbSci logo

ABSI AbSci Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapHigh Flyer

Momentum

Relative Strength (%)
1m+2.48%
3m+66.28%
6m+176.92%
1yr+123.91%
Volume Change (%)
10d/3m+14.13%
Price vs... (%)
52w High-23.44%
50d MA+10.68%
200d MA+98.35%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-53.69%
Return on Equity-43.52%
Operating Margin-1612.64%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of AbSci EPS forecast chart

Profile Summary

Absci Corporation is a generative artificial intelligence (AI) drug creation company. The Company combines AI with scalable wet lab technologies to create biologics for patients. It has built an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. The Company uses its platform to predict, identify, design, construct, screen, select and scale production of biologic drug candidates for its partners, and learn from the data it generates. Its SoluPro technology is a multiplex synthetic biology approach that overcomes the limitations of highest-throughput automation labs. The Company supports its generative AI designs with its wet lab's high-throughput functional validation capabilities. The Company applies generative AI to design optimal drug candidates based on target affinity, safety, manufacturability, and other traits.

Directors

Last Annual
December 31st, 2022
Last Interim
September 30th, 2023
Incorporated
October 5th, 2020
Public Since
July 22nd, 2021
No. of Employees
193
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
109,636,980

ABSI Share Price Performance

Upcoming Events for ABSI

Absci Corp at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum (Virtual)

Q4 2023 Absci Corp Earnings Release

Q1 2024 Absci Corp Earnings Release

Absci Corp Annual Shareholders Meeting

Q2 2024 Absci Corp Earnings Release

Similar to ABSI

Picture of 2Seventy Bio logo

2Seventy Bio

us flag iconNASDAQ Global Select Market

Picture of 4D Molecular Therapeutics logo

4D Molecular Therapeutics

us flag iconNASDAQ Global Select Market

Picture of AbCellera Biologics logo

AbCellera Biologics

us flag iconNASDAQ Global Select Market

Picture of Acadia Pharmaceuticals logo

Acadia Pharmaceuticals

us flag iconNASDAQ Global Select Market

Picture of Acelyrin logo

Acelyrin

us flag iconNASDAQ Global Select Market

FAQ